A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis

Table 2 Therapeutic data of study patients considered as a whole and by achievement of ID

Therapeutic features	All patients (n = 375)	Patients who did not achieve ID (n = 146)	Patients who achieved ID (n = 229)	P^#
Median MTX dose, mg/m² (n = 339)	12.8 (11.1–14.5)	13.1 (11.6–14.5)	12.8 (10.9–14.3)	0.2
Route of MTX administration				0.04
Oral	162/367 (44.1)	53 (37.3)	109 (48.4)
Parenteral	205/367 (55.9)	89 (62.7)	116 (51.6)
Treatment before MTX start
Intra-articular corticosteroid injections	17/372 (4.6)	3/143 (2.1)	14 (6.1)	0.07
Systemic corticosteroids	29/372 (7.8)	22/143 (15.4)	7 (3.1)	< 0.0001
Other synthetic DMARDs	21 (5.6)	14/143 (9.8)	7 (3.1)	0.006
Concomitant therapies during MTX administration
Intra-articular corticosteroid injections	165/374 (44.1)	67/145 (46.2)	98 (42.8)	0.52
Systemic corticosteroids	33/374 (8.8)	25/145 (17.2)	8 (3.5)	< 0.0001

ID inactive disease, MTX methotrexate, DMARDs disease modifying antirheumatic drugs
^#P value refers to the comparison between patients who did not achieve or achieved ID
Data are the number (%) unless otherwise indicated

ISSN: 1546-0096